AstraZeneca plc (ADR)(AZN)’s New Boss Shakes Things Up
From Insider Monkey - Free Hedge Fund and Insider Trading Data
January 17, 2013 - 7:39am
LONDON — AstraZeneca plc (ADR) (NYSE:AZN), the U.K.-based pharmaceutical giant, is currently beset by two main problems. First, its “blockbuster” treatments are steadily losing the patent protection that guaranteed high revenues. Indeed, its two biggest-selling products — Nexium for treating stomach acid and Crestor for treating cholesterol — will lose their U.S. patent protection during [...]
Continue reading this article »Share This Article: